More than a decade after describing the anti-inflammatory, antithrombotic and neuroprotective effects of activated protein C (APC) in ischemic stroke and six years after forming a company to move that hypothesis toward treatment, ZZ Biotech LLC has advanced its initial compound, 3K3A-APC, into the clinic.